Printer Friendly

Oncolytics Biotech granted Ras targeted herpes virus patent.

Oncolytics Biotech, Inc. (Calgary, Canada) announced that it has been granted United States Patent 6,649,157 entitled "Viruses for the Treatment of Cellular Proliferative Disorders." The claims in this patent cover the treatment of Ras mediated tumors using modified herpes viruses.

"We now have issued patents covering the treatment of cancers using three groups of viruses, including herpes, adenovirus and reovirus, that target the Ras pathway," said Dr. Matt Coffey, Vice President, Product Development of Oncolytics. "Herpes viruses having alterations in the (gamma)34.5 gene are commonly used in programs ranging from basic research to advanced clinical studies."

The issued claims in this patent cover the use of a herpes virus that has been modified by a mutation in the (gamma)34.5 gene, for the treatment of Ras mediated cancers. This is believed to cause this virus to provide specificity in Ras activated cancer cells.

Oncolytics is focused on the development of REOLYSIN, its proprietary formulation of the human reovirus, as a potential cancer therapeutic. Oncolytics' researchers have demonstrated that in vitro the reovirus is able to selectively kill human cancer cells that are derived from many types of cancer, including breast, prostate, pancreatic and brain tumors. They have also demonstrated successful results in a number of animal models. Phase I clinical trial results have indicated that REOLYSIN was well tolerated and that the reovirus demonstrated activity in tumors injected with REOLYSIN.

Oncolytics Biotech, Inc.

403-670-7377

www.oncolyticsbiotech.com
COPYRIGHT 2003 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:BIOTECH Patent News
Article Type:Brief Article
Geographic Code:1CANA
Date:Nov 1, 2003
Words:242
Previous Article:Genetic Technologies settles genetics patent lawsuits with Covance and Nuvelo.
Next Article:Momenta and Sandoz form complex pharmaceuticals strategic alliance.
Topics:


Related Articles
Infectious Notion.
GPC Biotech announces issuance of 2 patents for anti-fungal.
Antigenics adds patent to its dominant position.
Stressgen obtains new European patent for heat shock protein fusions.
Oncolytics announces issuance of third Canadian patent covering use of the reovirus to treat cancers.
Oncolytics announces issuance of second Canadian patent - therapeutic use of the reovirus for cellular proliferative disorders including cancer.
Oncolytics announces issuance of patent for reovirus clearance of ras-mediated neoplastic cells.
APPROVAL FOR U.K. CLINICAL TRIAL FOR REOLYSIN.
Oncolytics Biotech announces issuance of 23rd United States patent.
Oncolytics Biotech Announces Issuance of 8th Canadian Patent.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters